If new clinical data were to come out that greatly encouraged docs to prescribe Arixtra, that could conceivably have some impact on the market for generic (and branded) Lovenox. But the results you speak of are not new; in fact, I’ve already posted them myself on this board.
Whatever the reason, Arixtra continues to be a commercial dog and FDA approval of a generic is not going to change that all by itself.
News 
Market Data 
Discover 
